A Double-Blind Trial of Intravenous Thyrotrophin-Releasing Hormone in the Treatment of Reactive Depression
L. E. J. EVANS M.B., M.R.C.Psych.1,
P. HUNTER M.B., M.R.C.P.2,
R. HALL M.D., F.R.C.P.3,
MOIRA JOHNSTON M.B., M.R.C.Psych.4, and
V. MATHEW ROY M.D., D.C.P.5
1 Senior Registrar in Psychological Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP
2 Senior Registrar in Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP (Consultant Physician, Royal Salop Infirmary, Shrewsbury)
3 Professor of Medicine, University of Newcastle upon Tyne, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LD
4 Senior Registrar in Psychological Medicine, Royal Victoria Infirmary, Newcastle upon Tyne
5 Research Associate, Department of Medicine, Royal Victoria Infirmary, Newcastle upon Tyne, NE1 4LP (Associate Professor of Medicine, Medical College Hospital, Trivandrum 11, Kerala, India)
In a double-blind trial 600 µg. of thyrotrophin-releasing hormone (TRH) was compared with placebo given daily for four days to two groups of ten patients. There was no significant difference between the antidepressant effects of TRH and placebo.
Submitted on January 23, 1975
